Veradermics, Incorporated filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 10, 2026, covering the period ended September 30, 2026.

Key Highlights

  • Shares outstanding: 42,195,472 shares of common stock were outstanding as of November 5, 2026, according to the filing.
  • Exchange listing: The company's common stock, par value $0.00001 per share, trades on the New York Stock Exchange under the symbol MANE.
  • Company classification: Veradermics is designated as a non-accelerated filer, a smaller reporting company, and an emerging growth company, as indicated on the cover page.
  • Incorporation: The company is incorporated in Delaware, with principal executive offices at 470 James St., New Haven, CT 06513.
  • Lead product candidate: The filing identifies VDPHL01 as the company's primary product candidate, targeting pattern hair loss (PHL), with an NDA submission planned, according to the filing's forward-looking statements.
  • Shell company status: The registrant indicated it is not a shell company as defined in Rule 12b-2 of the Exchange Act.

Veradermics Files Quarterly Report for the Period Ended September 30, 2026

Veradermics, Incorporated (NYSE:MANE), a Delaware-incorporated biopharmaceutical company headquartered in New Haven, Connecticut, submitted its Form 10-Q for the quarterly period ended September 30, 2026. As of November 5, 2026, the company reported 42,195,472 shares of common stock outstanding. The filing confirms the company has met its Exchange Act reporting obligations and has submitted all required Interactive Data Files electronically in the preceding 12 months.

The company's cover page designates it as a non-accelerated filer, a smaller reporting company, and an emerging growth company under Rule 12b-2 of the Exchange Act. The filing notes that the company has not elected to use the extended transition period for complying with new or revised financial accounting standards under Section 13(a) of the Exchange Act. The common stock carries a par value of $0.00001 per share and is listed on the New York Stock Exchange.

The filing identifies VDPHL01 as the company's lead product candidate, described in its forward-looking statements as targeting pattern hair loss. The filing references plans for a future NDA submission for VDPHL01 and notes reliance on third parties for clinical trial conduct and drug substance manufacturing. The company cautions that all forward-looking statements "are only predictions" and are "subject to a number of known and unknown risks, uncertainties and assumptions," as stated in the filing's Special Note Regarding Forward-Looking Statements.

What Was Disclosed

Veradermics, Incorporated filed its Form 10-Q for the quarter ended September 30, 2026, disclosing 42,195,472 shares outstanding as of November 5, 2026, its emerging growth company status, and its NYSE listing under ticker MANE, with VDPHL01 cited as its lead product candidate.